Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play

TheFly reported connected January 14 that Goldman Sachs downgraded MLTX to Sell from Neutral and acceptable a terms people of $10, up from $8. The steadfast noted that sonelokimab’s advancement into Phase 3 for palmoplantar pustulosis provides an further opportunity, but it continues to presumption important approvability hazard successful hidradenitis suppurativa. Given VELA-2’s nonaccomplishment to conscionable its superior endpoint, Goldman Sachs does not judge the FDA’s procedural guidance meaningfully reduces support uncertainty.

Separately, earlier this month, connected January 9, H.C. Wainwright raised the terms people connected MoonLake Immunotherapeutics (NASDAQ:MLTX) to $32 from $26 and maintained a Buy rating. The steadfast noted that the result of the FDA Type B gathering provides a defined way toward regulatory registration.

MoonLake Immunotherapeutics (NASDAQ:MLTX) is simply a clinical‑stage biopharmaceutical institution that develops revolutionary Nanobody therapies to dainty inflammatory tegument and associated diseases. Its superior asset, sonelokimab, targets IL‑17A and IL‑17F to trim inflammation successful disorders similar hidradenitis suppurativa and psoriatic arthritis.

While we admit the imaginable of MLTX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.